Patent

High court rules against Indiana farmer in patent case

May 13, 2013
Associated Press
The Supreme Court has sustained Monsanto Co.'s claim that an Indiana farmer violated the company's patents on soybean seeds that are resistant to its weed-killer.
More

Lilly suing J&J for patent rights in Alzheimer's drug race

April 25, 2013
Bloomberg News
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
More

Court may decide if drugmakers can pay to delay generics

March 25, 2013
Associated Press
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
More

High court seems to favor Monsanto in patent case

February 19, 2013
Associated Press
The U.S. Supreme Court appeared likely Tuesday to side with Monsanto Co. in its claim that an Indiana farmer violated the company's patents on soybean seeds that are resistant to its weed-killer.
More

High-stakes fight over soybeans at high court

February 18, 2013
Associated Press
The court case poses the question of an Indiana farmer's actions violated the patent rights held by Monsanto, which developed seeds that survive when farmers spray their fields with Roundup weed-killer. The seeds dominate agriculture, including in Indiana, where more than 90 percent of soybeans are Roundup Ready.
More

Hoosier colleges discover patents aren't just for faculty anymoreRestricted Content

November 10, 2012
Chris O'Malley
Universities that once focused on faculty inventions now are encouraging students to pursue patents. Last year, 355 Purdue University students filed a patent, a 62-percent jump from 218 student-filed patents the previous year.
More

Dow Agro awarded $5.3M in patent-infringement case

October 2, 2012
The unsuccessful lawsuit filed by a subsidiary of Belgium-based Bayer Bioscience claimed that insect-resistant corn products from affiliates of Dow AgroSciences violated two of its patents.
More

Dow AgroSciences prevails in patent-infringement case

September 28, 2012
The lawsuit, filed in December 2010 by Bayer CropScience SA, charged that Indianapolis-based Dow AgroSciences' herbicide-tolerance technology infringed one of its patents.
More

Lilly challenging Biogen patent in London lawsuit

January 5, 2012
Bloomberg News
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
More

Patent expirations up pressure on Lilly

December 24, 2011
Eli Lilly and Co. lost patent protection on its $5-billion-a-year best-seller Zyprexa in October, plunging the company into the long-awaited zone of uncertainty that it calls “Years YZ.”
More

JONES: Patent reform is mixed bag for life sciences companiesRestricted Content

November 26, 2011
Kristin Jones / Special to IBJ
For Indiana's life sciences sector, the change both raises hopes and creates challenges for continued growth.
More

Lilly files suit over flea medication sales from Australia

November 11, 2011
Scott Olson
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication's trademark by reselling it to U.S. consumers online.
More

BorgWarner sues Cummins over patents on turbochargers

October 27, 2011
Bloomberg News
BorgWarner Inc., the world’s biggest maker of automatic-transmission parts for vehicles, filed a lawsuit accusing Cummins Inc. of infringing on three patents for a titanium wheel used in engine turbochargers.
More

Zyprexa era comes to an end for LillyRestricted Content

October 27, 2011
 IBJ Staff
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
More

Lilly: Vendors key after Zyprexa patent loss

October 24, 2011
J.K. Wall
Lilly's patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more on its 1,300 Indiana vendors.
More

Senate passes overhaul of patent system

September 10, 2011
Bloomberg News
The legislation would fundamentally alter the way patents are reviewed and mark the biggest change to U.S. patent law since at least 1952.
More

Despite sales spike, Effient has middling prospects

July 25, 2011
J.K. Wall
Remember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
More

Lilly CEO: Immigration, tax laws slow innovation

June 23, 2011
Bloomberg News
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
More

Growth in drug spending to slow as generics rise

May 18, 2011
Bloomberg News
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
More

Zimmer, peer sued over arthritic-knee treatments

April 26, 2011
Bloomberg News
Genzyme Corp., the drugmaker bought by Sanofi-Aventis SA this month, sued Zimmer Holdings Inc. and Anika Therapeutics Inc. alleging the companies’ treatments for arthritic knee pain infringe a patent.
More

Firm joins race with IU autism drug

April 9, 2011
J.K. Wall
The Indiana University School of Medicine has licensed a pediatric psychiatrist's patent on an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
More

Lechleiter: After the deluge, we'll be fine

March 16, 2011
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
More

Dow Chemical moves toward engineered corn patent

March 1, 2011
Associated Press
Dow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for its new strain of genetically engineered corn that it says will help farmers battle a new strain of "super-weeds."
More

Congress takes up major change in patent law

February 28, 2011
Associated Press
Congress has been trying for well over a decade to rewrite patent law, only to be thwarted by the many interested parties.
More

Intellectual property theft rising quicklyRestricted Content

February 26, 2011
Bob Kronemyer / Special to IBJ
Filching ranges from crude to highly sophisticated, experts say.
More
Page  1 2 3 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. In my opinion the estridge companies are crooks. They filed bankruptcy on their 'track housing' side of the business two weeks before they closed on one of my clients' homes. When my client first interviewed Estridge as a builder 6 months before, they specifically ASKED about the solvency of their business, knowing that some builders were struggling. Estridge truly misrepresented their financial situation at that time. I suppose I am more unhappy with the whole system than I am with the builder because what the heck==you can file bankruptcy on 'track homes' but still keep building and make money off of 'custom built' homes??? How ridiculous! They are all homes. How can a company be allowed to bilk thousands of dollars from their subcontractors but still be allowed to build houses?? they should have been made to pay back all their unpaid contractors before being allowed to profit from building any more houses! This alone makes them and the system crooks in my eyes. I would never build an estridge home and I would not recommend for my clients either. If they were truly 'bankrupt' how could they afford to keep building homes anyway??? The whole system needs fixed.

  2. I live a couple blocks east of the Angie's campus and my house is assessed for ~$160,000. If I could get that amount, let alone $384,000 (a 140% bonus), I'd sell in a minute. Either Angie's stockholders just got fleeced, or Angie's is getting about a 58% discount on their property taxes, if these properties are actually worth what they paid Mr. Oesterle for them. Which do you think is the case?

  3. Perhaps the IMA board is really to blame! They agreed to hire Charles. They can't seemingly find donors among themselves, or bring in new blood that will support the museums operating budget with an expanded museum and money to provide curators with something to do (ie buy art). The headlines of disarray at the museum and mass firings are hurting the reputation of the museum for some time to come. If people on the board had misgivings, perhaps they shpuld have more forcefully opposed efforts that they have seemingly been unable to fund, like expansion and the costs it has created!

  4. See, I told u Indyman and Dipsicle....this 8 days is overkill. It's barely worth a weekend....great job Tony George! Your dream has been fulfilled....he fans want the I r l back. Thats how good it was.....and that sucked.

  5. I have been in training for a short time now but right off I can see that safety and quality are the number one issues, my experience as of late has been a positive one, the employees along with Jeff the plant manager and the operation supervisor as well as the engineers are a highly motivated group of people, what an asset for the area to have and for company's in need of a quality metal products.

ADVERTISEMENT